v3.26.1
Segment Report (Tables)
12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information

Segment information for the year ended December 31, 2025 is presented below:

 

Schedule of Segment Reporting Information

   Pharmaceutical Operations   Premium Nutritional Supplements   Total Reportable Segments   Corporate / Other   Consolidated Total 
Revenue  -    21,796    21,796   -    21,796 
Cost of goods sold   -    4,231    4,231    -    4,231 
Research and development   

2,086,574

    -    2,086,574    -    

2,086,574

 
Selling, general and administrative   817,554    1,179,492    1,997,046    4,842,666    6,839,712 
Segment net loss   (2,904,128)   (1,161,927)   (4,066,055)   

(4,842,666

)   

(8,908,721

)
Other interest income (expense), net   -    -   -   263,824    263,824 
Net loss   (2,904,128)   

(1,161,927

)   (4,066,055)   (4,578,842)   (8,644,897)